Form 4: Hologic COO Exercises Stock Options and Sells Shares

Hologic's Chief Operating Officer, Mitchell Essex, exercised stock options and sold a portion of his holdings on December 4, 2024.

Summary

• Mitchell Essex, the Chief Operating Officer of Hologic Inc., engaged in multiple transactions involving the company's stock on December 4, 2024.
• He exercised stock options to acquire a total of 22,892 shares at prices ranging from $40.97 to $71.13.
• Following the exercise of these options, Mr. Essex sold 24,856 shares of common stock at a weighted average price of $76.339 per share.
• The sales were executed in multiple transactions with prices ranging from $76.31 to $76.54 per share.
• After these transactions, Mr. Essex directly owns 27,957 shares of Hologic common stock and 2,972 unexercised stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, which is neither positive nor negative in itself.

Industry Context

This is a routine filing related to insider transactions and is common for executives who hold stock options. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across publicly traded companies, including those in the medical device sector.
• Companies like Medtronic, Abbott, and Stryker also see similar filings from their executives.
• The reported transactions are within the normal range of executive compensation and stock management activities.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the volume of shares sold, but this is a normal part of executive compensation.

Key Dates

Keywords

Hologic, stock options, insider trading, Form 4, Mitchell Essex, equity securities, stock sale